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signed to risk factors that did not justify preventing anti-
coagulation according to the guideline tended to decrease
in both groups, this was more marked in the I group. Al-
most all physicians in both groups agreed that using this
form would help improving preventive anticoagulant pre-
scriptions. Nevertheless, 8/45 in the C group and 15/46
in the I group thought that it might hinder prescribing
treatments that could benefit patients. CONCLUSION:
Further analyses are underway to confirm that changes
observed in I group prescriptions reflect improved agree-
ment with the guidelines, and to assess variations across
wards and/or for different risk factors or combinations,
reflecting possible differences in supervision by senior
physicians, or demonstrating the need to improve the
documentation of specific recommendations.
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ASSOCIATED OUTCOMES OF INFLUENZA-LIKE-
ILLNESS AND CLINICAL INFLUENZA IN ITALY
Costa B, Arpinelli F, Bamfi F
Medical Department, Glaxo Wellcome S.p.A., Verona, Italy
OBJECTIVES: to estimate the natural history of influ-
enza and the associated resource utilization and General
Practitioner (GPs) workload in the Italian general popu-
lation. METHODS: during a three-month winter epi-
demic period, 199 GPs from one Northern and one
Southern Italian region reported daily the number of vis-
its because of Influenza-like-illness (ILI), Clinical influ-
enza (CI) and any other cause. Furthermore, the first 10
cases of CI in each month of the three-month period (a
total of 30 cases per GP), were carefully recorded and fol-
lowed up. RESULTS: about 200,000 visits were per-
formed by 199 GPs. ILI and CI accounted for 13.8% and
8.3% of all visits respectively. Six thousand and fifty
seven cases of CI were collected and evaluated for out-
comes. In our sample, 20% of patients (pts) were at risk
because of age (	65 years) or concurrent conditions. Al-
most all pts received at least one prescription for symp-
tomatic drugs, and 36% received antibiotics. Complica-
tions (primarily upper and lower respiratory tract bacterial
infections) affected 35% of pts. At risk pts had significantly
higher complication rate (OR  2.89; 95%C.I. 2.44–3.41),
and required more exams and hospitalizations than other
pts, accounting for most of direct costs associated with
CI. Pts with CI had an average of 5 days of absence from
work or school. CONCLUSIONS: influenza is associated
with significant morbidity in general and at risk popula-
tion, considerable working days lost and sizeable excess
workload for GPs.
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Respiratory syncytial virus (RSV), the leading cause of
lower respiratory tract infection in children, results in an es-
timated 90,000 hospitalizations and 4,500 deaths each year
in the United States. Children with underlying bronchopul-
monary dysplasia, prematurity or immunodeficiency are
known to be at high-risk for severe RSV illness. OBJEC-
TIVE: To evaluate research addressing the pharmaco-
economics of RSV immunoglobulin (RSV-IG) and palivi-
zumab, the only two available agents, to prevent RSV
infection among high-risk infants. METHODS: Studies in
English were identified from Medline (1993 to 2000) using
search terms like RSV-IG, palivizumab, costs, cost-effective-
ness. Additional studies were collected by searching bibliog-
raphies of identified articles and contacting study authors
and other experts. Data was abstracted from each study us-
ing a standardized reporting form. RESULTS: Cost per hos-
pitalization averted was the primary outcome measure
across most studies. Cost-effectiveness estimates of RSV-IG
have ranged from $3,800 to $8,800 per respiratory related
hospitalization prevented, to $24,000 per year of life saved,
to $102,608 to prevent hospitalization of a 3.3 kg infant.
Economic evaluation of palivizumab also indicate varied es-
timates ranging from expected savings of 39,107 per in-
fant to costs of $72,712 per hospitalization prevented. Two
recent studies compared both palivizumab and RSV-IG.
The cost-effectiveness of both agents varied widely among
different subgroups of premature infants based on their risk
of RSV hospitalization defined by gestational age and dura-
tion of respiratory support. Some studies used assumptions
about reduced mortality and morbidity that have not been
shown in the clinical trials. Also cost-effective models utiliz-
ing RSV hospitalization rates from clinical trials reported
less favorable results. CONCLUSION: Both RSV-IG and
palivizumab are very costly interventions. Inconsistent data
exists to conclude which is more cost-effective. In the ab-
sence of alternatives to the two agents, further research
needs to be performed to determine the overall cost-effec-
tiveness of immunoprophylaxis for RSV infection.
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OBJECTIVE: There is ongoing discussion in the Nether-
lands about the introduction of hepatitis B (HepB) vacci-
nation into the national immunisation program. The pur-
pose of this study was to analyze the cost-effectiveness of
general vaccination of newborns in addition to the current
policy, screening of pregnant women and subsequent im-
munisation of newborns from HBsAg- mothers (“screen 
vaccinate”) in comparison with the current strategy of
screening only (“screening only”), from a health care
payer perspective. METHODS: The incidence of HepB
infection over the next 50 years was simulated with a dy-
namic model, describing a population of age 0–60 years,
with 6 sexual activity classes (both for hetero- and homo-
sexual groups). Immigration from more endemic countries
was modelled as yearly additional incidence of carriers in
the population. Progress of disease after infection was
computed with a Markov-chain model, that predicted fu-
ture patient numbers, life-time costs of infection, and life-
years lost after infection. The main outcome parameter
was cost per life-years gained. Costs (in 1999 EUR) and
effects were discounted at 4%. RESULTS: Cost per life
year gained appeared to be highly sensitive to the as-
sumed percentage of carriers among immigrants, vaccina-
tion costs and to discounting of effects. Cost per life year
gained in the screen  vaccinate scenario ranged from
approximately EUR 25,000 (6% carriers among immi-
grants) to EUR 75,000 (1% carriers among immigrants).
If effects were not discounted, cost per life year gained
were below EUR 9,000 in all models explored.
CONCLUSIONS: Compared to other interventions, hep-
atitis B vaccination is not cost-effective in low endemic
countries such as the Netherlands. However, this conclu-
sion depends heavily on the convention to discount ef-
fects at a similar rate as costs. The application of stan-
dard methodology is unfavourable for programs that
prevent negative health outcomes in the mid- to long-
term.
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OBJECTIVE: 1) To describe the frequency and distribu-
tion of hospital antibiotics use. 2) To evaluate the appro-
priateness of the prescription to diagnostic and therapeu-
tic criteria. METHODS: It is an observational cross-
sectional study of 411 clinical records obtained by ran-
dom sampling over all hospital discharges between 01/
01/99 al 31/09/99. Information was sought on the fol-
lowing variables: identification, diagnosis, process indi-
cators, treatment changes and causes, indicators of clini-
cal evolution, and diagnostic and prescription criteria.
The information was collected and reviewed by the au-
thors. Criteria of infection and those of appropriateness
of prescription were obtained from the Centres for Dis-
ease Control and others scientific societies. RESULTS:
Antibiotics prescription was registered on the clinical
record in 25% of cases; 49% of antibiotic treatments
were prescribed in the hospital, 30% of them were treat-
ment changes, while 51% of antibiotic treatments were
prescribed in the reference hospital. Amoxicillin-Clavu-
lanate combination and ofloxacin account for 88% of
the prescriptions in the HMN and 76% of the total anti-
biotic treatments. Between 44% and 61% of the diagno-
sis were adequate to the criteria, with a mean of 54%,
and between 91% and 100% were appropriate prescrip-
tions. Mean treatment length was 9.6 days, and only
14% of the urinary tract infection treatment length was
correct; an intravenous catheter was kept 80% of the
treatment. DISCUSSION: While most of the antibiotic
prescription in this study were appropriate to the clinical
diagnosis, only half of the diagnosis were in keep with
the diagnostic criteria used in this study and the urinary
tract infection as well as the intravenous duration treat-
ment appear to be long. The consequences of these find-
ings are increased cost and iatrogenia. The adequacy of
diagnosis to objective criteria and the duration on treat-
ment, especially intravenous treatment, are the main ar-
eas for improving. The recommended strategies are: 1)
utilization consensus 2) training programs 3) medical au-
dits 4) development of diagnostic and therapeutic criteria
adapted to the hospital.
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OBJECTIVES: Influenza is a highly contagious disease
that remains a major cause of morbidity and mortality in
Europe. The socio-economic impact of the disease is un-
derestimated. The study aimed to model options for in-
fluenza management in three European countries (France,
Germany, United Kingdom). METHODS: Cost-of-illness
(COI) and cost-effectiveness (CE) models were developed
to assess the economics of influenza prevention for de-
fined adult groups (employed people, elderly, high-risk
patients). The initial models were developed based on in-
ternational and UK published data. Treatment efficacy
and the general epidemiology of influenza were assumed
to be similar for the three countries. The adaptation of
the general models was based on: 1) a country specific lit-
erature review was performed to collect baseline models
parameters: patient demographics, epidemiology, attack
rate, occurrence probabilities, complications and death,
current treatment patterns, general and specific clinical
practice guidelines, clinical effectiveness of current thera-
pies, medical resource utilization and productivity loss;
